
|Articles|October 1, 2003
PHASE I CLINICAL TRIALS FOR PSORIASIS TX
Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
DeepSeek-R1 Outperforms ChatGPT-4o in Urticaria Clinical Queries
4
Abeona Initiates First Commercial Treatment of Zevaskyn for RDEB
5



















